imig2014 Cape Town Final Scientific Programme October 2014

Size: px
Start display at page:

Download "imig2014 Cape Town Final Scientific Programme 21-24 October 2014"

Transcription

1 imig2014 Cape Town Final Scientific Programme October 2014 Day 0-21 October 2014 Welcome to Cape Town! Registrati Welcome Cocktails Cape Town Internatial Cference Centre Cape Town Internatial Cference Centre 00.1 Dr T Makgoba 1900 Welcome to Cape Town and South Africa Dear Colleagues, imig 2014 in Cape Town will be host to 160+ high quality oral presentatis, about 30 poster discussis and around 150 posters. The morning sessis starting at 08:00 will be 2 hours and the afterno sessis 1½ hours in durati. Poster discussis will occur at 17:00 Days 1 and 2, with poster viewings throughout the day the first two days. Except for the plenary sessis, each oral presentati will be 15 minutes, to be strictly enforced by the Chairs armed with vuvuzela s. The weather for October will be mostly sunny, with temperatures ranging from C (55-70 F). Please pack a light rain jacket if you are venturing out, as Cape Town and Cape Peninsula weather can be unpredictable. We look forward to a very good meeting over the next 3 days, and to furthering our comm quest for preventi and cure. Sincerely, Jim tewaternaude

2 Day 1-22 October Registrati Opening Plenary S Mutsaers Invited Speakers appear in Bold J tewaternaude 10.1 C Alifrangis 0815 Next Generati Sequencing: Genome-Directed Precisi Medicine in 10.2 R Salgia From Chaos to Mitochdrial Functiality: What the Fractal? 10.3 R Weinberg 0905 imig Special Keynote Lecture: Cancer Stem Cells as Target Pathways 10.4 L Kazan-Allen 0930 The Global Asbestos Landscape: Past, Present and Future 1000 Coffee/Poster Viewing 11 Epidemiology J Peto 12 Immunotherapy 1030 A Nowak 13 Optimising Surgery 1030 W Vigneswaran R Ehrlich D Sterman I Opitz 11.1 J Peto 1030 Anti-Mesothelin Vaccine CRS-207 Plus Worldwide Epidemiology of 12.1 R Hassan 1030 Chemotherapy as Frt-Line Treatment for MPM 13.1 D Waller 1030 P/D: The Best There Is? 11.2 G Nels F Baumann C Magnani J Murray M Mencobi M Metintas 1200 The Burden of in an Asbestos-Exposed Cohort: The MINKS Study Epidemiological Indicators of an Envirmental Exposure to Asbestos-Like Carcinogenic Fibers: Methodological Issues Malignant after Exposure to Chrysotile in Balangero, Italy: An Update Clinicopathological Correlati of Asbestos-Related Diseases in Former Miners Clinicopathological Features of Patients with Malignant in a Multicenter, Retrospective Study Identificati of Variables Affecting Malignant : An Ecologic Study 12.2 A Cook J Aerts E Mo L Calabro S Anguille E Mo 1200 A Phase Ib Clinical Trial of the CD40 Activating Antibody CP-870,893 in Combinati with Cisplatin and Pemetrexed in MPM Dendritic Cell-Based Vaccinati under Reduced Tumor-Induced Immune Suppressi in MPM Targeting Tumor Stroma of with Chimeric Antigen Receptor T Cells Tremelimumab at an Optimized Dosing Schedule in Secd-Line Patients: A Phase II Single-Arm Study Survival Advantage Following Dendritic Cell Vaccine Therapy in MPM: A Phase I/II Clinical Trial A Phase I Clinical Trial of Anti- Mesothelin mrna Chimeric Antigen Receptor T-Cell Therapy in Patients 13.2 J van Meerbeeck J Steele E Ruffini H Fevzi Batirel A Sharkey Chairs 1200 European Surgical Trials: MARS2 vs. EORTC After Surgical Treatment: A Critical Appraisal Multiple-Variable Adjusted Prognostic Model for Optimal Surgical Approach to MPM: A Clinicopathological Analysis 167 Patients Surgery after MARS Trial: Does Change in Surgical Technique Affect Survival Outcomes? The Effects of an Intential Transiti from Extrapleural Pneumectomy to Extended Pleurectomy/Decorticati Discussi: How Should We Select Surgical Patients Today and How Will We Select Them in Five Years?

3 11.8 Chairs 1215 Discussi 12.8 H Kindler 1215 with Progressive MPM PD-1: Integrating Immune Checkpoint Modulati into Therapy for MM 13.8 Chairs 1215 Discussi 14 Animal Models & Preclinical Studies 14.1 H Yang S Lansley R Lake R Lake A Nowak Lunch/Poster Viewing 1230 Lunch/Poster Viewing 1230 Lunch/Poster Viewing 1330 D Barbe 15 Periteal 1330 E Choi 16 Surgery Symposium 1330 W Weder R Lake M Deraco J Friedberg Periteal : Overcome Aspirin Delays the Limits of Chemotherapy and Growth by Targeting High M Deraco D 1330 Optimize the Results of the CRS-HIPEC Sugarbaker Mobility Group Box 1 Protein through Translatial Research Fibroblast Growth Factor Receptor (FGFR) Inhibitors Significantly Retard Tumour Growth in Two Orthotopic Murine Models of Statins Do Not Alter the Incidence of in Asbestos-Exposed Mice or Humans Aspirin Has No Significant Effect Asbestos-Induced in MexTAg Mice Csistent with Data from a Human Cohort Imaging and Modulating Hypoxia in a Murine Model of Malignant 15.2 H Kindler D Baratti J Leinwand V Kepenekian 1430 Integrating Systemic Therapy and Novel Therapeutics for Periteal Malignant Malignant Periteal : Incorporati of Novel Pathological Grading into a Recently Proposed TNM Classificati Improves Outcome Predicti Tissue Platinum Localizati in Multimodal Intraperiteal Chemotherapy for Malignant Periteal Role of Systemic Perioperative Chemotherapy in Diffuse Malignant Periteal Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperiteal Chemotherapy (HIPEC): A Multi- Institutial Study 16.2 J Friedberg 1345 The State of the Art Technique for Extrapleural Pneumectomy The State of the Art Technique for Lung-Sparing Surgery 16.3 D Waller 1400 Persalising Surgery 16.4 W Weder R Rintoul 1430 Save the Lung or Take the Lung? Advantages and Disadvantages of Extrapleural Pneumectomy and Pleurectomy/Decorticati MesoVATS: Where Do We Go From Here? 14.6 S Snedd 1445 Understanding the Mutatis of Malignant (MM): A Study of Mouse Homologues of Human MM 15.6 Chairs 1445 Discussi 16.6 M Culligan 1445 Complicatis of Extended Pleurectomy/Decorticati vs. Extrapleural Pneumectomy in 138 Patients Undergoing Surgery for MPM 1500 Tea/Poster Viewing 1500 Tea/Poster Viewing 1500 Tea/Poster Viewing 17 Multimodality P Baas 18 Nursing and Supportive Care 1530 L Darlis 19 Biomarkers J Creaney L Lang-Lazdunski M Hesdorffer O Roe 17.1 W Buikhuisen Maintenance Therapy after First Line Treatment 18.1 M Hesdorffer Promoting Entry into Clinical Trials and 1530 Improving Access to Specialist Treatment and Care 19.1 R Bueno Molecular Prognostic Factors in 1530 Practice

4 17.2 I Opitz W Weder R Bueno J Friedberg Roundtable Discussi 1645 Intraoperative Adjuvant Therapies for MPM: Worthwhile or Waste of Time? Hemithoracic Radiotherapy after Neoadjuvant Chemotherapy and EPP: Final Results of the Randomized Phase II Trial SAKK 17/04 Neoadjuvant Therapy and Surgery Radical Pleurectomy and Intraoperative Photodynamic Therapy for the Treatment of Epithelial MPM Best Approach for Patients with Unresectable MPM Poster Discussi Sessi Periteal Animal Models Free Evening 18.2 L Darlis M Culligan P Magabanyane A Scherpereel L Reinstein 1645 Improving Outcomes in : An Internatial Approach to Meeting Nurses Educatial Needs Developing and Coordinating a Specialist Program of Treatment and Care Palliative Care in Kuruman: Setting Up a Community Oasis Pulmary Rehabilitati at Home is Feasible and Exhibits Significant Benefits in Patients with MPM Treated by Chemotherapy 19.2 R Cornelissen 19.3 J van Meerbeeck S Kao D Jean 1630 Intratumoral Macrophage Phenotype and CD8+ T Lymphocytes Predict Local Tumor Outgrowth at the Interventi Site in MPM 1600 A Breath Test for Diagnosing MPM Importance of Supportive Resources for Patients and Caregivers 19.6 N Maskell 1645 SWAMP Trial Poster Discussi Sessi Biomarkers Free Evening Expressi of Secreted Protein Acidic and Rich in Cysteine (SPARC) in MPM is Associated with Short Survival TERT Promoter Mutatis in MPM: Strg Associati with Sarcomatoid Histological Subtype Poster Discussi Sessi Asbestos Issues Imaging Free Evening

5 Day 2-23 October Medallists' Plenary 0800 A Linegar S Mutsaers 20.1 M-C Jaurand 0800 Cell Lines and Animal Models 20.2 B Robins 0830 Biomarkers and Immunotherapy 20.3 S Albelda Wagner Medallist 2014 Molecular Genetics 21.1 K Birnie S Maki- Nevala Immunogene Therapy for : The Lg and Winding Road 0930 Title to be announced 1000 Coffee/Poster Viewing 1030 M Carbe T Seiwert Y Sekido D Barbe M Phillips 1145 Novel Therapeutics 1030 D Fennell 23 Epidemiology G Nels Y Sekido R Kratzke J tewaternaude Loss of mir-223 and Over-Expressi of Target Protein Stathmin Regulate Cell Motility in Malignant Exome Sequencing Reveals Novel Recurrent Mutatis in Asbestos-Exposed Lung Adenocarcinoma and Malignant Genomic Profiling of Malignant Reveals Comm BAP1, CDKN2A/B, NF2, and INPP4B Aberratis, but a Paucity of Targetable Changes Hippo Pathway Inactivati in Malignant Cells The Dual PI3K/mTOR Inhibitor GDC Bypasses Multicellular Resistance of Spheroids 22.1 D Fennell 1030 Novel Therapeutics 23.1 J McCullough S Albelda R Salgia L Mutti A Clive 1130 Tumor-Associated Macrophages Mediate Resistance to Pegylated Arginine Deiminase in MPM 22.6 D Schrump V Ascoli 1200 BAP1 Analysis in Familial 22.7 G Reid 1200 Histamine Dihydrochloride in the Treatment of Role of Focal Adhesi Kinase (FAK) Inhibiti in CAIX Inhibitors: Targeting Metabolism The Bristol Randomised Ctrolled Trial of Zoledric Acid in Malignant Pleural Disease: A Proof of Principle, Pilot Study Mithramycin Induces DNA Damage, Depletes Sp1 and Activates p53 Signaling to Mediate Senescence and Autophagy of MPM Cells In Vitro and In Vivo TargomiRs: Targeted Delivery of a Novel MicroRNA Mimics as an Approach to Treating MPM 23.2 J Phillips R Jes N van Zandwijk V Panou D Kielkowski H Fevzi Batirel 1200 Asbestos Blues: A History of Asbestos Mining in South Africa The South African Legacy of Asbestos: Then and Now Ctaminati of the South African Envirment from Asbestos Mining and Related Activities in Australia: Data from the Australian Registry Overrepresentati of Malignant Periteal amg Females in a Cohort of 296 Danish Patients Mortality in a Cohort Born in the Early 20th Century in the Prieska District, South Africa Asbestos Ctrol Strategic Plan in Turkey's Determinati of the Magnitude of the Problem

6 21.8 M Carbe 1215 BAP1 Mutatis in Sporadic 22.8 L Moro 1215 Agist Activati of Estrogen Receptor Beta Sensitizes MPM Cells to Cisplatin Cytotoxicity 23.8 S Burgers 1215 Occasial Exposure to Asbestos: What is the Risk? 24 Persalised Therapy Symposium 1230 Lunch/Poster Viewing 1230 Lunch/Poster Viewing 1230 Lunch/Poster Viewing 1330 B Robins 25 Multimodality D Waller 26 Optimising Radiotherapy 1330 R Abratt J Steele J Sorensen C Sime 24.1 D Barbe 1330 Spheroids and Drug Sensitivity 25.1 S Burgers C Alifrangis G Middlet B Robins 1415 Drug Resistance or Sensitivity: How to Use Molecular Events to Pick Therapy Signalling: Why D t the TKIs or Antiangiogenesis Agents Work Well? Immunological Therapy: Who and How to Treat Based Likely/Unlikely Respses 25.2 I Opitz I Opitz S Bolukbas 1415 Combining Chemotherapy and/or Radiati with Surgery, Before, After, Never or Both: Ratiale and Evidence Multimodality Benefit Score: Improved Patient Selecti for MPM Patients Undergoing Surgery after Inducti Chemotherapy Phase I Intracavitary Cisplatin-Fibrin Chemotherapy after Resecti for MPM Patients (INFLuenCe-Meso) Predictors of Survival and Progressi-Free Survival after Radical Pleurectomy followed by Chemotherapy for Epithelioid MPM 26.1 C Sime A Rimner K Cengel M De Perrot 1415 Radiorespsiveness, Ratiale, and Roles for Radiati Therapy for Radiotherapy Techniques and Outcomes after Radical Pleurectomy for Future Horizs for Radiati Therapy for : Radiobiology and Immunotherapy Neoadjuvant Radiati Therapy in Patients Receiving Extrapleural Pneumectomy 24.5 L Schunselaar 1430 Primary Tumor Cultures of MPM for Multiple Drug Testing 25.5 A Sharkey 1430 Does the Timing of Chemotherapy Affect Outcome following Radical Surgery for MPM? 26.5 C Sime 1430 Prophylactic Irradiati of Surgical Tract Sites for MPM in the Era of Radical Pleurectomy 24.6 J Quispel- Janssen 1445 Persalized Treatment for Patients with MPM Based Primary Tumor Cultures 25.6 W Weder 1445 Perioperative Outcome for Patients Undergoing Inducti Chemotherapy followed by EPP Compared to P/D 26.6 Chairs 1445 Discussi 1500 Tea/Poster Viewing 1500 Tea/Poster Viewing 1500 Tea/Poster Viewing 27 Clinical Trials 1530 H Kindler 28 Biomarkers S Knuutila 29 Pathology 1530 M-C Jaurand A Scherpereel J van Meerbeeck J Murray

7 27.1 P Baas 1530 FAK Inhibitor VS-6063 (Defactinib) Targets Cancer Stem Cells which are Enriched by Standard of Care Chemotherapy 28.1 J Creaney 1530 Challenges in Development of Biomarkers 29.1 A Hjerpe 1530 Discussis Guidelines for Cytopathologic Diagnosis of Malignant 27.2 M Keegan 1545 Determinati of Biomarker Respse in a Phase II Window of Opportunity Study of Defactinib (VS-6063), a Focal Adhesi Kinase (FAK) Inhibitor, in Subjects with Resectable MPM 28.2 A Lint 1545 A Prognostic Index for Estimating Survival in a Large Series of Patients with MPM 29.2 N Vorajee 1545 Pathalogical Challenges in the Diagnosis of Pleural Malignant 27.3 P Szlosarek A Mansfield A Cook H Kindler 1645 Phase I Study of ADI-PEG 20 in Combinati with Pemetrexed and Cisplatin (TRAP) in Patients with Malignant Systematic Review of Respse Rates of Sarcomatoid MPMs in Clinical Trials Immunological Effects of the Glucocorticoid Dexamethase in the Ctext of Chemoimmunotherapy for Multi-Arm, N-Randomized, Open- Label Phase Ib Study to Evaluate FP- 1039/ GSK Given in Combinati with Standard-of-Care Chemotherapy Regimens in NSCLC and MPM with Deregulated FGF Pathway Signaling Poster Discussi Sessi 28.3 C Blanquart S Albelda M Kirschner R Hassan 1645 Study of the Chemokine CCL2 in MPM Cellular Interfer Respse as a Predictor of Chemosensitivity Use of a 6-microRNA Signature for Prognosis in MPM Successful Implementati of a Comprehensive Bio- Specimen Bank for Poster Discussi Sessi 29.3 F Galateau- Salle R Rintoul D Jean T Chernova 1645 MESOBANK: A Clinicobiological Database for Epidemiological and Translatial Research for MESOBANK UK: An Internatial Bioresource for Tissue Double Inactivati of NF2 and LAST2, Members of the Hippo Pathway, in a Tumor Subgroup of MPMs Lg-Fibre Carb Nanotubes and Asbestos- Induced Pleural Lesis Exhibit a Comm Molecular Signature Poster Discussi Sessi Novel Therapies Pathology Epidemiology Gala Dinner Kirstenbosch Gala Dinner Kirstenbosch Gala Dinner Kirstenbosch

8 Day 3-24 October Social Advocacy 31.1 K Ruff R Spoor S Kao M Hindry S Kisting M Hesdorffer 0800 L Kazan-Allen 32 Surgery & Staging R Bueno 33 Immunology 0800 T Nakano P Camay S Bolukbas S Albelda S Kazan E Algotss 0945 The Critical Role Scientists and Health Professials Can Play to Prevent Asbestos-Related Harm: Recent Examples and Lesss Learned Limitatis the Right to Legal Recourse for Victims in South Africa Mortally Wounded : Stakeholder Perceptis of the MPM Diagnostic Process The Role of Victims Associatis for Preventi and Compensati of Asbestos Diseases Community Perspectives Compensati for Asbestos- Related Diseases, including, in South Africa The Voice of the Patient in the United States: Advocacy Efforts and Accomplishments of the Applied Research Foundati Patients Rights to Compensati from United States Asbestos Bankruptcy Trust Funds: An Update Asbestos Ctaminati at Khiba School: Possible Legal Interventis 32.1 A Sharkey E Alley O Mercier W Richards S Bolukbas S Hasegawa 0915 How Useful are Subjective Variables in Predicting Outcome of Radical Surgery for MPM? Posterior Intercostal Lymph Nodes Affect Prognosis for Surgery-Based Treatment of MPM and Should Be Csidered N2 Lymph Nodes Factors Affecting Survival after Extrapleural Pneumectomy for pn2 MPM Does Neoadjuvant Chemotherapy Improve Overall Survival Amg Patients with Pathological N2-N3 MPM Who Undergo Surgical Resecti? Abdominal Recurrence in Patients Undergoing Lung-Sparing Radical Pleurectomy and Macroscopic Complete Resecti for MPM Outcome of 104 Csecutive Surgical Candidates with MPM: A 10-Year Experience at Hyogo College of Medicine 32.7 Chairs 0930 Poster Discussi D Sterman L Mutti W Lesterhuis L Wu S Kao T Seiwert 0915 J van Meerbeeck E Mo 0945 A Phase I/II Clinical Trial Evaluating Two Different Chemotherapy Regimens in Combinati with Intrapleural Adenoviral-Mediated Interfer- Alpha (SCH , Ad.hIFNa2b) Gene Transfer for MPM Anti-CTLA4 Checkpoint Blockade in Patients with Improving Immune Checkpoint Blockade Efficacy in : A Systems Biology Approach Tumor-Infiltrating Regulatory T Cells after Local Radiati Can Be Reversed by Systemic Blockade of the Immune Checkpoints in Murine Programmed Death Ligand 1 (PD-L1) Expressi is an Independent Adverse Prognostic Factor in MPM T-Cell Inflamed Phenotype, PD- L1, and ICOS Expressi Identify a Subgroup of Malignant s Potentially Amenable to Immunotherapy Approaches Expressi of Immune Checkpoint Programmed Death 1 and its Ligands MPM Cells A PD1-CD28 Switch Receptor is Able to Augment Mesothelin- Directed Chimeric Antigen Receptor T-Cell Therapy in a Resistant In Vivo Model of Human Tumor

9 1000 Coffee 1000 Coffee 1000 Coffee 34 Imaging 1030 S Armato A Nowak R Gill J Coolen S Armato 1115 Surgery & Staging D Sugarbaker 36 Molecular Therapeutics 1030 L Mutti J Coolen H Fevzi Batirel P Szlosarek Assessing Treatment Respse in 2014: How Should We Deal with Immunotherapy, PET, and Biomarkers? Preliminary Assessment of Apparent Diffusi Coefficient in Biphasic MPM by Diffusi- Weighted MRI (DWI) Evaluati of Early Chemotherapy Respse and Outcome of Inoperable MPM Patients by Diffusi-Weighted MRI CT-Based Tumor Volume: Correlati with Surgical Volume 35.1 L Lang- Lazdunski S Bolukbas R Camer G Frendl 1115 Pleurectomy/Decorticati, Hyperthermic Pleural Lavage with Povide-Iodine, Prophylactic Radiotherapy and Systemic Chemotherapy: Experience in 100 Csecutive Patients Pretreatment Score Correlates with Outcomes in Patients Undergoing Lung-Sparing Multimodality Treatment Aerosolized Combinati of CoSeal and Autologous Blood Helps Reduce Air Leaks following Pleurectomy for Incidence and Risk Factors for Venous Thromboembolism in Patients with MPM in the Postoperative Period: A 4-Year Retrospective Analysis 36.1 M Keegan F Pentimalli V Serre- Beinier J Creaney 1115 The Cancer Stem Cell Inhibitors VS-6063 (Defactinib) and VS Exhibit Synergistic Anticancer Activity in Preclinical Models of Reactivating RBL2/p130 Oncosuppressive Functi as a New Possible Therapeutic Strategy for Pleural Involvement of MIF Signaling in Malignant Identificati of Neo-Antigens using Whole Exome Sequencing in a Murine Model of 34.5 S Armato 1130 Toward Volumetric Respse Criteria for 35.5 H Kindler 1130 IMIG/IASLC Staging 36.5 M MacFarlane 1130 Targeting Cell Death Pathways in Preclinical Models of MPM 34.6 C Straus 1145 Natural History Tumor Volume Growth as a Ctributory Factor in Assessing Respse to Chemotherapy in MPM 35.6 R Gill 1145 North American Multicenter Feasibility Trial of Volumetric CT for the Clinical Staging of MPM 36.6 M Locke 1145 Targeting Resistance to Arginine Depleti Therapy in 40 Closing Plenary 1200 D Fennell 1215 J tewaternaude Welcome to imig Lunch & B Voyage

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY

More information

Update on Clinical Trials and Foundation Funded Grants

Update on Clinical Trials and Foundation Funded Grants Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Surgical therapy of. who should be operated

Surgical therapy of. who should be operated SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich

More information

Malignant pleural mesothelioma P/D vs. EPP

Malignant pleural mesothelioma P/D vs. EPP 3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

Malignant Mesothelioma: an Update

Malignant Mesothelioma: an Update Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image

More information

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012 Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Educational Session. Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School, Japan. Mechanisms of asbestos-induced carcinogenesis

Educational Session. Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School, Japan. Mechanisms of asbestos-induced carcinogenesis Tuesday, Aug. 31 Room A Time: 8:00-8:10 Opening Remarks Time: 8:10-8:35 The mesothelial cell ES01 Time: 8:35-9:00 Educational Session Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School,

More information

An update in Mesothelioma and Thymoma Management

An update in Mesothelioma and Thymoma Management An update in Mesothelioma and Thymoma Management ASCO 2014 update Khalid Alsaleh King Saud University FRCPC, FACP, MSc Mesothelioma Outline Outline Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting

More information

Educational Session. Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School, Japan. Mechanisms of asbestos-induced carcinogenesis

Educational Session. Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School, Japan. Mechanisms of asbestos-induced carcinogenesis Tuesday, Aug. 31 Room A Time: 8:00-8:10 Opening Remarks Time: 8:10-8:35 The mesothelial cell ES01 Time: 8:35-9:00 Educational Session Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School,

More information

Mesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam

Mesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Mesothelioma 2014 Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Disclosures Grants from Pfizer and Roche Advisor for MSD and Verastem Once upon a time. http://amlbenzene.net/diseases-asbestos.htm

More information

Malignant Pleural Mesothelioma in Singapore

Malignant Pleural Mesothelioma in Singapore RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

Post-operative intrapleural chemotherapy for mesothelioma

Post-operative intrapleural chemotherapy for mesothelioma Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy

More information

Mesothelioma Applied Research Foundation www.curemeso.org

Mesothelioma Applied Research Foundation www.curemeso.org Mesothelioma Applied Research Foundation www.curemeso.org Board of Directors Michael Becich PhD Gen. Steven Blum Lee Krug MD David Ettinger MD Axel Ranier Richard Mosca Erica Iacono Terry Lynch Hanne Minz

More information

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,

More information

THE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA

THE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA THE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA Mitchell Keegan, Ph.D. Vice President of Development, Verastem, Inc. 1

More information

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious

More information

Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy?

Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy? JBUON 2015; 20(2): 376-380 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy,

More information

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)

More information

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland

More information

Pre-workshop exercise

Pre-workshop exercise Setting research priorities for mesothelioma workshop 10 th November 2014 Pre-workshop exercise Your individual ranking of unanswered questions about the diagnosis, treatment and care of mesothelioma Please

More information

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental

More information

Management of mesothelioma

Management of mesothelioma Management of mesothelioma Jan.vanmeerbeeck@ugent.be Amsterdam, March 6, 2010 1 management Palliation Symptomatic care Pain Breathlessness Radiotherapy Chemotherapy Surgery Radical (intention to cure)

More information

FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS. Jonathan Pachter, Ph.D.

FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS. Jonathan Pachter, Ph.D. FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.

More information

Screening, early referral and treatment for asbestos related cancer

Screening, early referral and treatment for asbestos related cancer Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung

More information

Robert Bristow MD PhD FRCPC

Robert Bristow MD PhD FRCPC Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

International Symposium on Malignant Pleural Mesothelioma

International Symposium on Malignant Pleural Mesothelioma International Symposium on Malignant Pleural Mesothelioma LONDON 2015 Friday 6th & Saturday 7th November 2015 Jumeirah Carlton Tower Hotel Cadogan Place Knightsbridge London SW1X 9PY United Kingdom Dear

More information

Update on Mesothelioma

Update on Mesothelioma November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical

More information

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year

More information

Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database

Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database Featured Article Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database Valerie W. Rusch 1, Dorothy Giroux 2 1 Memorial Sloan-Kettering Cancer Center, New

More information

Asbestos-Related Cancer Research and Prevention

Asbestos-Related Cancer Research and Prevention Asbestos-Related Cancer Research and Prevention Professor Nico van Zandwijk Asbestos Diseases Research Institute University of Sydney International Conference on Asbestos Awareness and Management 18 November

More information

Lung cancer is not just one disease. There are two main types of lung cancer:

Lung cancer is not just one disease. There are two main types of lung cancer: 1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Clinical Indications and Results Following Chest Wall Resection

Clinical Indications and Results Following Chest Wall Resection Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division

More information

PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.

PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic

More information

P L E U R A L M E S O T H E L I O M A

P L E U R A L M E S O T H E L I O M A For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural

More information

MESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC

MESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC MESOTHELIOMA Not Just a Late Night Commercial Graciela Hoal, RN, MSN, ACNP-BC Saturday Session Thoracic Surgery Nurse Practitioner Greater Los Angeles Veteran Affairs Objectives Course Objectives: Discuss

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.

More information

Cancer and the immune system: can we beat cancer at its own game?

Cancer and the immune system: can we beat cancer at its own game? Cancer and the immune system: can we beat cancer at its own game? Andrew R. Haas, MD, PhD Assistant Professor of Medicine University of Pennsylvania Medical Center Philadelphia, Pa Why can t immune

More information

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History

More information

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from

More information

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI

More information

The following information is only meant for people who have been diagnosed with advanced non-small cell

The following information is only meant for people who have been diagnosed with advanced non-small cell Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC

More information

Multimodal management of malignant pleural mesothelioma: where are we today?

Multimodal management of malignant pleural mesothelioma: where are we today? SERIES THORACIC ONCOLOGY Multimodal management of malignant pleural mesothelioma: where are we today? Paul E. Van Schil 1, Isabelle Opitz 2, Walter Weder 2, Christophe De Laet 1, Andreas Domen 1, Patrick

More information

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant

More information

Recruiting now. Could you help by joining this study?

Recruiting now. Could you help by joining this study? Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate

More information

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,

More information

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.

More information

LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH

LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International

More information

Moving forward, where are we with Clinical Trials?

Moving forward, where are we with Clinical Trials? Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance

INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance A. Bernheim Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance OVER-MyR is funded by the European Commission within its FP7 specific

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient

Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that

More information

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University

More information

ASBESTOS MANAGEMENT REVIEW A CRITICAL REVIEW OF MEDICAL MANAGEMENT IN MALIGNANT PLEURAL MESOTHELIOMA - AUSTRALIA, 2011

ASBESTOS MANAGEMENT REVIEW A CRITICAL REVIEW OF MEDICAL MANAGEMENT IN MALIGNANT PLEURAL MESOTHELIOMA - AUSTRALIA, 2011 ASBESTOS MANAGEMENT REVIEW A CRITICAL REVIEW OF MEDICAL MANAGEMENT IN MALIGNANT PLEURAL MESOTHELIOMA - AUSTRALIA, 2011 Dr Malcolm Feigen Senior Radiation Oncologist Radiation Oncology Centre Austin Health

More information

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

More information

Cancer patients waiting for potentially live-saving treatments in UK

Cancer patients waiting for potentially live-saving treatments in UK Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.

More information

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT 1) TOPIC OF THE EVENT MALIGNANT PLEURAL DISEASE 2) SUGGESTED TITLE : Approach to Pleural Cancer: State-of-the-Art 3) TYPE OF EVENT Course Native

More information

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research

More information

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the

More information

Clinical Trials for Patients with

Clinical Trials for Patients with Clinical Trials for Patients with Malignant Pleural Mesothelioma Lee M. Krug, M.D. Memorial Sloan-Kettering Cancer Center New York, New York Challenges in MPM Clinical Trials Mesothelioma is a rare disease,

More information

Gastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/

Gastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Gastric Cancer Description: Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the second

More information

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer

More information

Please see the LUCADA data manual v3.1.3, available in the downloads section

Please see the LUCADA data manual v3.1.3, available in the downloads section National Lung Cancer Audit Frequently Asked Questions What dataset should be used? Please see the LUCADA data manual v3.1.3, available in the downloads section What does LUCADA stand for? LUCADA stands

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Treating Mesothelioma - A Quick Guide

Treating Mesothelioma - A Quick Guide Treating Mesothelioma - A Quick Guide Contents This is a brief summary of the information on Treating mesothelioma from CancerHelp UK. You will find more detailed information on the website. In this information

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

Na#onal Asbestos Forum 2013: Advance in Medical Research on Asbestos- Related Diseases

Na#onal Asbestos Forum 2013: Advance in Medical Research on Asbestos- Related Diseases Na#onal Asbestos Forum 2013: Advance in Medical Research on Asbestos- Related Diseases Professor Nico van Zandwijk Asbestos Diseases Research Ins#tute Content List of Asbestos- Related Diseases Epidemiology

More information

One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3

One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3 1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point

More information

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine

More information

Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma

Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma I d like to welcome everyone, thanks for coming out to our lunch with experts. The faculty today are great people in the thoracic

More information

Outline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice

Outline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment Radiation Biology Outline Introduction: Predictive assays in radiation therapy Examples for specific tumors Immunotherapy Summary

More information

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The

More information

Lung Cancer and Mesothelioma

Lung Cancer and Mesothelioma Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,

More information

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) 2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Wednesday Oct 7th, 2015 Congress Center (Hörsaal 1 3) Marien Hospital Herne Accreditation by the Medical Chamber

More information

Treatment of mesothelioma in Bloemfontein, South Africa

Treatment of mesothelioma in Bloemfontein, South Africa European Journal of Cardio-thoracic Surgery 24 (2003) 434 440 www.elsevier.com/locate/ejcts Treatment of mesothelioma in Bloemfontein, South Africa W.J. de Vries*, M.A. Long Cardiothoracic Department,

More information

Malignant pleural mesothelioma: outcome of limited surgical management

Malignant pleural mesothelioma: outcome of limited surgical management Interactive Cardiovascular and Thoracic Surgery 2 (2003) 30 34 Institutional review Thoracic general Malignant pleural mesothelioma: outcome of limited surgical management Peter G. Phillips a, George Asimakopoulos

More information

Lessons learned from the Western Australian experience with mesothelioma

Lessons learned from the Western Australian experience with mesothelioma Lessons learned from the Western Australian experience with mesothelioma Alison Reid, Western Australian Institute for Medical Research In partnership with Nick de Klerk, Nola Olsen, Jan Sleith, Geoffrey

More information